− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 Achieving At Least an ACR 20 Response Compared to 29.2% in the Placebo Group at Week 12 1
− TAK-279.
− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 121
− Based on the.
Takeda TSE4502NYSETAK today announced positive topline results from its randomized doubleblind placebocontrolled multipledose Phase 2b trial evaluating TAK279 an investigational oral allosteric tyrosine kinase 2 TYK2 inhibitor with next generation selectivity in people with active psoriatic arthritis.